MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Published 2014 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 15, Issue 6, Pages 656-666

Publisher

Elsevier BV

Online

2014-04-17

DOI

10.1016/s1470-2045(14)70155-x

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Ask a Question. Answer a Question.